Multimodality treatment of esophagus cancer

Current status and future perspectives in the United States

Research output: Contribution to journalArticle

Abstract

Investigations over the past three decades have resulted in multimodality therapy as the standard of care today for the management of stage II and III esophageal cancer in the United States. During this same time period, there has been a shift in the dominant histology and primary location from squamous cell cancer of the midesophagus to adenocarcinoma of the distal esophagus and gastroesophageal junction. The results of large clinical trials and meta-analyses demonstrate that trimodality therapy (chemoradiation followed by esophagectomy) improves local-regional control and overall survival compared to either single-modality surgery or the sequence of chemotherapy followed by surgery. Concomitant chemoradiation without surgery improves survival and local-regional control compared to radiotherapy alone in patients with squamous cell histology. Thus, surgical and nonsurgical approaches are available for treatment of esophageal cancer in the United States. Current investigations focus on the integration of biologics into current therapies and the identification of prognostic and predictive biomarkers.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalEsophagus
Volume7
Issue number1
DOIs
StatePublished - Mar 2010

Fingerprint

Esophageal Neoplasms
Histology
Esophagogastric Junction
Squamous Cell Neoplasms
Esophagectomy
Survival
Therapeutics
Standard of Care
Biological Products
Meta-Analysis
Radiotherapy
Biomarkers
Epithelial Cells
Clinical Trials
Drug Therapy

Keywords

  • Chemoradiation
  • Esophagus
  • Surgery

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Multimodality treatment of esophagus cancer : Current status and future perspectives in the United States. / Forastiere, Arlene A.

In: Esophagus, Vol. 7, No. 1, 03.2010, p. 1-6.

Research output: Contribution to journalArticle

@article{d4e59c890fb942bab202de7d4133e945,
title = "Multimodality treatment of esophagus cancer: Current status and future perspectives in the United States",
abstract = "Investigations over the past three decades have resulted in multimodality therapy as the standard of care today for the management of stage II and III esophageal cancer in the United States. During this same time period, there has been a shift in the dominant histology and primary location from squamous cell cancer of the midesophagus to adenocarcinoma of the distal esophagus and gastroesophageal junction. The results of large clinical trials and meta-analyses demonstrate that trimodality therapy (chemoradiation followed by esophagectomy) improves local-regional control and overall survival compared to either single-modality surgery or the sequence of chemotherapy followed by surgery. Concomitant chemoradiation without surgery improves survival and local-regional control compared to radiotherapy alone in patients with squamous cell histology. Thus, surgical and nonsurgical approaches are available for treatment of esophageal cancer in the United States. Current investigations focus on the integration of biologics into current therapies and the identification of prognostic and predictive biomarkers.",
keywords = "Chemoradiation, Esophagus, Surgery",
author = "Forastiere, {Arlene A.}",
year = "2010",
month = "3",
doi = "10.1007/s10388-009-0226-8",
language = "English (US)",
volume = "7",
pages = "1--6",
journal = "Esophagus",
issn = "1612-9059",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Multimodality treatment of esophagus cancer

T2 - Current status and future perspectives in the United States

AU - Forastiere, Arlene A.

PY - 2010/3

Y1 - 2010/3

N2 - Investigations over the past three decades have resulted in multimodality therapy as the standard of care today for the management of stage II and III esophageal cancer in the United States. During this same time period, there has been a shift in the dominant histology and primary location from squamous cell cancer of the midesophagus to adenocarcinoma of the distal esophagus and gastroesophageal junction. The results of large clinical trials and meta-analyses demonstrate that trimodality therapy (chemoradiation followed by esophagectomy) improves local-regional control and overall survival compared to either single-modality surgery or the sequence of chemotherapy followed by surgery. Concomitant chemoradiation without surgery improves survival and local-regional control compared to radiotherapy alone in patients with squamous cell histology. Thus, surgical and nonsurgical approaches are available for treatment of esophageal cancer in the United States. Current investigations focus on the integration of biologics into current therapies and the identification of prognostic and predictive biomarkers.

AB - Investigations over the past three decades have resulted in multimodality therapy as the standard of care today for the management of stage II and III esophageal cancer in the United States. During this same time period, there has been a shift in the dominant histology and primary location from squamous cell cancer of the midesophagus to adenocarcinoma of the distal esophagus and gastroesophageal junction. The results of large clinical trials and meta-analyses demonstrate that trimodality therapy (chemoradiation followed by esophagectomy) improves local-regional control and overall survival compared to either single-modality surgery or the sequence of chemotherapy followed by surgery. Concomitant chemoradiation without surgery improves survival and local-regional control compared to radiotherapy alone in patients with squamous cell histology. Thus, surgical and nonsurgical approaches are available for treatment of esophageal cancer in the United States. Current investigations focus on the integration of biologics into current therapies and the identification of prognostic and predictive biomarkers.

KW - Chemoradiation

KW - Esophagus

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=77954788418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954788418&partnerID=8YFLogxK

U2 - 10.1007/s10388-009-0226-8

DO - 10.1007/s10388-009-0226-8

M3 - Article

VL - 7

SP - 1

EP - 6

JO - Esophagus

JF - Esophagus

SN - 1612-9059

IS - 1

ER -